Make an inquiry
Refer a patient

We noticed you are on our US page. Want to switch regions? Choose from the options:

UK
AU
ES
GenesisCare - logo
Find a location
Find a doctor
GenesisCare - logo
Make an inquiry
Refer a patient

We noticed you are on our US page. Want to switch regions? Choose from the options:

UK
AU
ES
Find a location
Find a doctor
Make an inquiry
Refer a patient
  • Healthcare Professionals
  • Latest research
  • Publications
  • Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
20 Oct 2021

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

written by
Sylvester John E, MD
Matthew R.Smith, Neal Shore, Teuvo L.Tammelac Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Marie-Aude Le Berre, Ateesha F.Mohamed, Dawn Odom, Jennifer Bartsch, Amir Snapir, Toni Sarapohja, Karim Fizazi Journal: European Journal of Cancer , volume: Volume 154 , pages 138-146
US Genesis Logo

GenesisCare

About us
COVID-19
Careers

Website policies

Website terms of use
HIPAA notice of privacy practices
Su información. Sus derechos. Nuestras responsabilidades
Notice of non-discrimination
Aviso de No Discriminación
Financial conflict of interest in research
Language assistance services
Privacy policy
Do not sell my personal information
Cookie Preferences

Contact us

Make an inquiry
Request medical records

Media & Social

News Room - What's been happening
Facebook
Twitter
LinkedIn
Youtube
Vimeo
Facebook

Copyright © 2023 GenesisCare. All Rights Reserved.